In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers ...
The rapid rise of weight loss drugs is generating a host of new product lines as companies hope to land on the right side of ...
Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers ...
Lilly’s Trulicity and Novo Nordisk’s Ozempic have rocketed into Medicare’s top-10 spending list. That sets them up to be ...
Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and ...
Bryan Walsh is an editorial director at Vox overseeing the climate, tech, and world teams, and is the editor of Vox’s Future ...
Apple helped popularize smartphones. Now it’s going to push the world into the next era of telecommunications, this one ...
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on ...
NEW YORK — Nestlé, the maker of frozen food brands like Stouffer’s and DiGiorno, is slimming down with a new line of meals ...
While the UK stock market is rising, the Diageo share price is falling. Here, Edward Sheldon looks at what’s going on with ...
Unrivaled access, premier storytelling, and the best of business since 1930.